CurrentBlue Cross Blue Shield - MassachusettsPolicy 427

Intra-articular hyaluronan (viscosupplementation) injections — Coverage & Prior Authorization

Defines BCBSMA coverage and prior authorization expectations for intra-articular hyaluronan injections (knee and other joints) for commercial members and describes formulary status and medical policy stance; applies to members with pharmacy benefits and to outpatient retail pharmacy requests.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyIntra-articular hyaluronan (viscosupplementation) injections — Coverage & Prior Authorization

Policy CodePolicy 427

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit prior authorization requests for outpatient retail pharmacy hyaluronan products to BCBSMA Pharmacy Operations using the Massachusetts Standard Form (eForm) or by phone/fax.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

427Policy ID

Non-coveredFormulary status

J73xxHCPCS

eFormPA form

Since 1998History

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determination and Rationale

Overall policy determination

Coverage stance summarized from evidence review

General coverage conclusion: Intra-articular hyaluronan injections of the knee are considered not medically necessary; injections for other joints are considered investigational.

All FDA-approved and off-label uses are not covered due to insufficient evidence to show improved health outcomes per BCBSA Policy 2.01.31; exceptions may be considered only under Individual Consideration and, if granted, covered under the pharmacy benefit as outlined in Policy 071.

This policy follows the Blue Cross Blue Shield Association review and does not cover intra-articular hyaluronan injections as a standard therapy. Specifically, all FDA‑approved and off‑label uses are not covered because the scientific evidence is insufficient to demonstrate improved health outcomes. If an exception is granted through Individual Consideration, coverage is provided only under the pharmacy benefit as described in Policy 071.

The evidence base for intra‑articular hyaluronan is mixed. Systematic reviews and meta‑analyses across joints report variable results, and some analyses find saline injections have comparable effects to hyaluronan for hip pain. Randomized trials and reviews for shoulder, hip, and hand osteoarthritis are heterogeneous, contributing to uncertainty about clinically meaningful benefit.

Per the BCBS Association policy adopted here, intra‑articular hyaluronan injections of the knee are considered not medically necessary. Injections for all other joints are considered investigational and are not covered outside of an approved Individual Consideration exception.

Billing and Coding

HCPCS codes listed as investigational/in policyHCPCSNot Covered

J7318	mg.
J7320	Hyaluronan or derivative, Genvisc 850, for intra-articular injection 1 mg.
J7321	Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular
J7322	Hyaluronan or derivative, Hymovis, for intra-articular injection mg.
J7323
J7324
J7325	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection mg.
J7326	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
J7327
J7328	Hyaluronan or derivative, GELSYN-3, for intra-articular injection, 0.1 mg.

1–10 of 14

1/2

Prior Authorization, Submission, and Denial Risk

Prior Authorization

Prior Authorization Required

Prior authorization is required for intra-articular hyaluronan products listed in this policy. Use the Massachusetts Standard Prior Authorization eForm when submitting requests. Physicians may call or fax Pharmacy Operations for assistance or to submit supporting documentation.

Pharmacy Operations: Tel: 1-800-366-7778; Fax: 1-800-583-6289
Massachusetts Standard Form for Medication Prior Authorization Requests (eForm): http://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam/assets/023%20E%20Form%20medication%20prior%20authorization%20instruction%20prn.pdf
Submit individual consideration requests (if clinical criteria not met) to: Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department, 25 Technology Place, Hingham, MA 02043

Denial Risk

Denial Risk for Non‑Covered / Investigational Use

Requests for uses considered non-covered or investigational (including intra-articular hyaluronan injections for joints other than the knee, and knee uses deemed not medically necessary per BCBSA guidance) are at high risk of denial. If an exception is granted under Individual Consideration, coverage may be limited and processed under the pharmacy benefit per policy guidance.

Clinical Background

Knee osteoarthritis is a common, disabling condition characterized by pain and loss of function. Viscosupplementation — intra‑articular injection of hyaluronan (including cross‑linked hylans) — is proposed to restore synovial fluid viscoelasticity and improve pain and function. However, clinical trial results and systematic reviews show small and inconsistent treatment effects, and reviewers conclude viscosupplementation is unlikely to improve net health outcomes for knee osteoarthritis compared with available alternatives.

Key Terms

Hyaluronan / hylan definition and properties

DefinitionHyaluronan: a naturally occurring macromolecule that is a major component of synovial fluid and contributes to its viscoelastic properties.

Hylan (cross-linked hyaluronan)Chemically cross‑linked forms of hyaluronan with increased molecular weight; referred to as hylans.

Physiologic roleContributes to synovial fluid viscoelasticity; in osteoarthritis both HA chain length and synovial HA concentration are decreased.

Therapeutic rationaleExogenous hyaluronan/hylan is used to restore synovial fluid viscoelasticity as a viscosupplement to improve pain and function in OA.

Examples (document mentions)Products include hylan G-F 20 and various sodium hyaluronate preparations referenced in the policy.

Intra-articular hyaluronic acid (viscosupplementation) definition

Applicable Settings

Note

Office / site‑of‑care: outpatient retail pharmacy (prior auth via Pharmacy Operations)

This policy applies to outpatient retail pharmacy requests; prior authorization for pharmacy benefit coverage and exceptions must be obtained through BCBSMA Pharmacy Operations.

Policy applies to Commercial Members (HMO, POS, PPO, Indemnity) and requires submission via Pharmacy Operations.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyIntra-articular hyaluronan (viscosupplementation) injections — Coverage & Prior Authorization

Policy CodePolicy 427

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit prior authorization requests for outpatient retail pharmacy hyaluronan products to BCBSMA Pharmacy Operations using the Massachusetts Standard Form (eForm) or by phone/fax.

SourceLink

On This Page

Policy basis: BCBSA Policy 2.01.31 — intra-articular hyaluronan injections for the knee considered not medically necessary; investigational for other joints
Individual Consideration exceptions are reviewed by Pharmacy Operations and, if approved, may be covered only under the pharmacy benefit (see Policy 071)

Note

How to Request Prior Authorization / Individual Consideration

For requests that do not meet clinical criteria in this policy, submit an Individual Consideration with relevant clinical documentation using the Massachusetts eForm or by contacting Pharmacy Operations via phone or fax. Failure to use the MA standard prior authorization eForm or to provide required documentation may delay processing or increase the likelihood of denial.

Use the MA Standard Prior Authorization eForm for Medication Prior Authorization Requests (link above).
Phone: 1-800-366-7778; Fax: 1-800-583-6289
Mail: Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department, 25 Technology Place, Hingham, MA 02043

DefinitionIntra-articular hyaluronic acid (viscosupplementation): injectable hyaluronan preparations administered into joints to treat symptoms of osteoarthritis.

Intended effectProposed to restore synovial fluid viscoelasticity and thereby reduce pain and improve function in osteoarthritic joints.

Common target jointsKnee is the primary target; literature also evaluates hip, shoulder (glenohumeral), ankle, hand/base of thumb, and first metatarsophalangeal joint.

Evidence summary (policy context)The evidence base is mixed with randomized trials and systematic reviews across joints; cited trials/meta-analyses report variable effectiveness and small treatment effects in some studies.

Examples of cited studies/guidelinesMultiple RCTs and systematic reviews are cited (e.g., Petterson 2019; meta-analyses for hip and shoulder; ACR/OARSI and other guideline documents referenced).